BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Dear Doctor Letter (Rote-Hand-Brief) on Revlimid® (lenalidomide): Risk of liver diseases

2012.12.10

Active substance: lenalidomide

Information for health care professionals regarding the risk of liver diseases in connection with the use of Revlimid® (lenalidomide) in the presence of other risk factors.

Fachinformation Revlimid® (Lenalidomid) PDF, 453KB, File is accessible

(SPC Revlimid® - available in German only)

Download DHPC / Information letter , Download_VeroeffentlichtAm_EN PDF, 268KB, File is accessible